These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 32691891)
1. Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants. Salerno SN; Edginton A; Gerhart JG; Laughon MM; Ambalavanan N; Sokol GM; Hornik CD; Stewart D; Mills M; Martz K; Gonzalez D; Clin Pharmacol Ther; 2021 Jan; 109(1):253-262. PubMed ID: 32691891 [TBL] [Abstract][Full Text] [Related]
2. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population. Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994 [TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. Prakash C; Fan B; Ke A; Le K; Yang H Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634 [TBL] [Abstract][Full Text] [Related]
4. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. Li J; Kankam M; Trone D; Gammon G Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645 [TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of sildenafil in extremely premature infants. Gonzalez D; Laughon MM; Smith PB; Ge S; Ambalavanan N; Atz A; Sokol GM; Hornik CD; Stewart D; Mundakel G; Poindexter BB; Gaedigk R; Mills M; Cohen-Wolkowiez M; Martz K; Hornik CP; Br J Clin Pharmacol; 2019 Dec; 85(12):2824-2837. PubMed ID: 31475367 [TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib. Wu F; Krishna G; Surapaneni S Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148 [TBL] [Abstract][Full Text] [Related]
7. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers. Li A; Yeo K; Welty D; Rong H Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603 [TBL] [Abstract][Full Text] [Related]
8. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990 [TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706 [TBL] [Abstract][Full Text] [Related]
10. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690 [TBL] [Abstract][Full Text] [Related]
11. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study. Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A Clin Pharmacol Ther; 2021 Jun; 109(6):1618-1630. PubMed ID: 33283268 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method. Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962 [TBL] [Abstract][Full Text] [Related]
13. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients. Einolf HJ; Zhou J; Won C; Wang L; Rebello S Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787 [TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron. Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092 [TBL] [Abstract][Full Text] [Related]
15. PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co-Administered with CYP3A4 Inhibitors. Umehara K; Parrott N; Schindler E; Legras V; Meneses-Lorente G Clin Pharmacol Ther; 2024 Oct; 116(4):1130-1140. PubMed ID: 39023380 [TBL] [Abstract][Full Text] [Related]
16. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models. Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361 [TBL] [Abstract][Full Text] [Related]
17. Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19. Chang M; Chen Y; Ogasawara K; Schmidt BJ; Gaohua L Cancer Chemother Pharmacol; 2024 Oct; 94(4):549-559. PubMed ID: 39110202 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997 [TBL] [Abstract][Full Text] [Related]
19. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors. Guo J; Zhou D; Li Y; Khanh BH Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137 [TBL] [Abstract][Full Text] [Related]
20. The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects. Lee S; Kim AH; Yoon S; Lee J; Lee Y; Ji SC; Yoon SH; Lee S; Yu KS; Jang IJ; Cho JY Drug Metab Pharmacokinet; 2021 Feb; 36():100368. PubMed ID: 33348240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]